Jupiter Asset Management Ltd. Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Key Points

• Jupiter Asset Management Ltd. has significantly increased its stake in BioCryst Pharmaceuticals, owning approximately 1.03% of the company after acquiring 971,040 shares in the first quarter, raising their total to over 2.14 million shares.
• Analysts have issued varied price targets for BioCryst Pharmaceuticals, with Needham & Company setting a target at $17.00 and HC Wainwright at $30.00, while the average consensus price target stands at $16.70.
• Currently, institutional investors hold 85.88% of BioCryst Pharmaceuticals' stock, indicating strong backing by hedge funds and investment firms.

Jupiter Asset Management Ltd. increased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 82.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,148,969 shares of the biotechnology company's stock after purchasing an additional 971,040 shares during the quarter. Jupiter Asset Management Ltd. owned approximately 1.03% of BioCryst Pharmaceuticals worth $16,117,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. XTX Topco Ltd increased its holdings in shares of BioCryst Pharmaceuticals by 314.8% in the 1st quarter. XTX Topco Ltd now owns 87,389 shares of the biotechnology company's stock worth $655,000 after purchasing an additional 66,320 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of BioCryst Pharmaceuticals by 69.3% in the first quarter. GSA Capital Partners LLP now owns 278,552 shares of the biotechnology company's stock valued at $2,089,000 after acquiring an additional 114,068 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of BioCryst Pharmaceuticals by 10.1% in the first quarter. Federated Hermes Inc. now owns 184,904 shares of the biotechnology company's stock valued at $1,387,000 after acquiring an additional 16,947 shares in the last quarter. Mackenzie Financial Corp lifted its position in shares of BioCryst Pharmaceuticals by 37.3% in the first quarter. Mackenzie Financial Corp now owns 116,258 shares of the biotechnology company's stock worth $872,000 after buying an additional 31,596 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth about $125,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

BCRX stock traded down $0.19 during trading on Friday, hitting $7.95. The stock had a trading volume of 7,969,651 shares, compared to its average volume of 3,386,599. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31. The stock has a market capitalization of $1.66 billion, a P/E ratio of -30.58, a PEG ratio of 1.30 and a beta of 1.10. The company's 50-day moving average price is $9.54 and its two-hundred day moving average price is $8.74.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on BCRX shares. Needham & Company LLC reissued a "buy" rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, June 25th. Barclays boosted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Bank of America raised their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday, July 1st. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $16.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.